[Effects and side effects of benzbromaron in the initial treatment of hyperuricemia and gout. Results of a field study on 3899 patients].
In a collective of 3899 out-patients, the effect of uric acid reduction of benzbromarone was tested. Ten days after beginning of treatment, a uric acid concentration of 5.1 to 5.7 mg/100 ml had been obtained. Three months after beginning of therapy, uric acid values were at 4.9 mg/100 ml, independently of age and sex. As side-effects were observed:diarrhoea in 1% (n = 41) of the treated patients, furthermore, 0,8% (n = 31) complained of gastro-intestinal trouble such as pressure over the stomach, nausea, sensation of fullness and epigastric pain. Only in 2 of the 3899 patients (0.05%) the appearance of a renal colic was observed.
D001553:Benzbromarone / Q000009:adverse effects / Q000627:therapeutic use*; D001572:Benzofurans / Q000627:therapeutic use*; D003967:Diarrhea / Q000139:chemically induced; D005260:Female; D006073:Gout / Q000188:drug therapy*; D006801:Humans; D007669:Kidney Calculi / Q000139:chemically induced; D008297:Male; D009325:Nausea / Q000139:chemically induced; D014527:Uric Acid / Q000652:urine
D001572:Benzofurans; D014527:Uric Acid; D001553:Benzbromarone
Wirkungen und Nebenwirkungen von Benzbromaron bei der Initialbehandlung von Hyperurikämie und Gicht. Ergebnisse eines Feldversuches mit 3899 Patienten.